Congenital Methemoglobinemia Type II-Clinical Improvement with Short-Term Methylene Blue Treatment.

Abstract excerpt

We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia type II. He has a CYB5R3 compound heterozygote mutation, causing a cytochrome-b(5) reductase deficiency. Since the MB treatment regimen has commenced, his methemoglobin level has been significantly lower. He has shown modest behavioral improvements (as assessed on the Achenbach...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Child, Preschool
• Share to Mutation